# **Supplemental information**

# Membrane Position of Ibuprofen Agrees with Suggested Access Path Entrance to Cytochrome P450 2C9 Active Site

Karel Berka,<sup>a</sup> Tereza Hendrychová,<sup>a</sup> Pavel Anzenbacher,<sup>b</sup> Michal Otyepka<sup>\*a</sup> <sup>a</sup> Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic <sup>b</sup> Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

updated 4. July 2011

### Figure S1. Multiple alignment of the human CYP2C9 with sequences used in the

#### experimental topology studies.

Multiple alignment of the human wt CYP2C9 (swissprot accession number P11712), crystal structure of the engineered CYP2C9 (pdbid: 1OG2 and 1OG5) and with rat CYP2B1 (P00176) and rabbit CYP2B4 (P00178) with annotated membrane topology and mutations. Multiple alignment was calculated by ClustalW2<sup>1</sup> and visualized with Jalview 2.6<sup>2</sup>. Red color denotes mutations used for preparation of the engineered crystal structure. Green color shows the amino acids which are responsible for the interactions with cytochrome P450 reductase<sup>3</sup>. Annotations for membrane topology are colored as follows: blue for the sequence accessible, violet for the sequence inaccessible and pink for regions where the data are mixed. Data were taken from Refs. <sup>4-8</sup>.

P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	1 - MDSLVVLVLCLSCLLLLSLW <mark>ROSSGRGK LPP GPTPLPY IGNILQIGI</mark> KDISKSLTNLSK5 30	9 9 0 0
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	60 VYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFG <mark>IVFS</mark> NGKK 1 60 VYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKK 1 41 VYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKK 1 61 <mark>KYGDVFTVHLGP</mark> RPVVMLCGTDTIKEALVGQAEDFSGRGTIAVIEPI <mark>FKEYGVIFA</mark> NGER 1 61 KYGDVFTVYLGSRPVVVLCGTDAIREALVDQAEAFSGRGK <mark>IAVVDPIFQGYGVIFA</mark> NGER 1	19 19 20 20
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	120 W <mark>KEIRRFSLMT</mark> LRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVIC 1 120 WKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVIC 1 101 WKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVIC 1 121 WKALRRFSLATMRDFGMGKRSVEERIQEEARCLVEELRKSQGAPLDPTFLFQCITANIIC 1 121 WRALRRFSLATMRDFGMGKRSVEERIQEEARCLVEELRKSKGALLDNTLLFHSITSNIIC 1	79 79 50 80 80
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	180 SIIFHKRFDYKDQQFLNLMEK_NENI <mark>K</mark> ILS <mark>SPWIQICNNFSPIIDYFPGTHNK</mark> LLKNVAF 2 180 SIIFHKRFDYKDQQFLNLMEKLNENIEILSSPWIQVYNNFPALLDYFPGTHNKLLKNVAF 2 161 SIIFHKRFDYKDQQFLNLMEKLNENIEILSSPWIQVYNNFPALLDYFPGTHNKLLKNVAF 2 181 SIVFGERFDYTDRQFLRLLEL <mark>F</mark> YRTFSLLS <mark>SFSSQVFEFFSGF</mark> LKYFPGAHRQISKNLQE 2 181 SIVFGKRFDYKDPVFLRLLDLFFQSFSLISSFSSQVFELFPGFLKHFPGTHRQIYRNLQE 2	39 39 20 40 40
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	240 MKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLE <mark>NTAVDLFGAGT</mark> 2 240 MKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGT 2 221 MKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGT 2 241 ILDYIGHIVEKHRATLDPSAPRDFIDTYLLRMEKEKSNHHTEFHHENLMISLLSLFFAGT 3 241 INTFIGQSVEKHRATLDPSNPRDFIDVYLLRMEKDKSDPSSEFHHQNLILTVLSLFFAGT 3	99 99 80 00
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	300 TSTTLRYALLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYI3 300 ETTSTTLRYALLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYI3 281 ETTSTTLRYALLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYI3 301 ETSSTTLRYGFLLMLKYPHVAEKVQKEIDQVIGSHRLPTLDDRSKMPYTDAVIHEIQRFS3 301 ETTSTTLRYGFLLMLKYPHVTERVQKEIEQVIGSHRPPALDDRAKMPYTDAVIHEIQRLG3	59 59 40 60
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	360 DLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLH <mark>DNKEFPNPEMF</mark> DPHHFLDEGGNF 4 360 DLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNF 4 341 DLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNF 4 361 DLVPIGVPHRVTKDTMFRGYLLPKNTEVYPILSSALH <mark>DPQYFDHPDSF</mark> NPEHFLDANGAL 4 361 DLIPFGVPHTVTKDTQFRGYVIPKNTEVFPVLSSALHDPRYFETPNTFNPGHFLDANGAL 4	19 19 00 20 20
P11712 CYP_2C9/1-490 1OG2 CYP_2C9/30-490 1OG5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	420 KKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASV4 420 KKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASV4 401 KKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASV4 421 KKSEAFMPFSTGKRICLGEGIARNELFLFFTTILQNFSVSSHLAPKDIDLTPKESGIGKI4 421 KRNEGFMPFSLGKRICLGEGIARTELFLFFTTILQNFSIASPVPPEDIDLTPRESGVGNV4	79 79 50 80
P11712 CYP_2C9/1-490 10G2 CYP_2C9/30-490 10G5 CYP_2C9/1-475 P00176 CYP_2B1/1-491 P00178 CYP_2B4/1-491	480 PPFYQLCFIPV4480 PPFYQLCFIPV4461 PPFYQLCFIPVHHHH4481 PPTYQICFSAR4481 PPSYQIRFLAR4	90 90 75 91 91

### Table ST1 – The diffusion coefficient changes upon membrane insertion.

The diffusion coefficients (D) were calculated with Einstein-Stokes equation from the linear part of the mean square displacement of protein within the simulations. The diffusion coefficients given by this study seem to be too big in comparison with experimental data for several reasons: (i) the use of homogenous DOPC membrane, and (ii) a simplified unitedatom Berger force field model of the DOPC/SPC membrane/water environment. Even though the calculated diffusion is by order of magnitude bigger than experimental data, we still can conclude that the diffusion of the solubilized CYP in water is quicker than the diffusion of the CYP bound on the membrane.

Diffusion Type and System	Source	D	
		$10^{-7} \text{ cm}^2/\text{s}$	
Total, model in water	This study	$7.0 \pm 0.26$	
Total, model in DOPC membrane	This study	$1.6 \pm 0.14$	
Lateral, model in DOPC membrane	This study	$2.1\pm0.23$	
Lateral, WALP23 †	Ref. <sup>9</sup>	$0.5 \pm 0.1$	
Lateral, CYP2C2 in ER membrane	Ref. <sup>10</sup>	$5.8 \cdot 10^{-3} \pm 0.2 \cdot 10^{-3}$	

†artificial helical TM segment in DOPC/DOPG 3:1 membrane.

## Figure S2 – Comparison between initial (green) and final (blue) model of wt CYP2C9.

Panel A and B show the protein and membrane changes upon simulation, respectively. The protein is shown in cartoon representation and phosphorous atoms from the membrane are shown as spheres. While the protein core did not changed significantly during the simulation, the membrane topology and parts of protein responsible for the interaction with the membrane show slight rearrangement as discussed in paper. The figure was prepared in Pymol 0.99rc6<sup>11</sup>.

В

А

# Figure S3 – The evolution of RMSD of CYP2C9 on the membrane in three individual simulations used in selection of the appropriate model.

The simulation was triplicated after first 10 ns. The simulations were then equilibrated after approximately 20 ns.



# Figure S4 – Detailed structure of the transmembrane helical segment of CYP2C9.

The transmembrane helix is shown in magenta. The N-terminal part is not perpendicular to the membrane, nor is penetrating beyond charged groups in the luminal part of membrane. The helix is kinked in the Arg21 position. The figure was prepared in Pymol 0.99rc6<sup>11</sup>.



### Figure S5 – Channel opening and closing during membrane simulations of CYP2C9.

.

Channel opening analysis provided by Vlad Cojocaru on our two independent simulations. The most open channel is solvent channel followed to some extent by channels 2c and 2ac as seen in coloring in the picture.



## **Figure S6 – Schematics of model preparation.**

First, position of transmembrane helix in membrane has been evaluated by short 10 ns united atom simulation. The transmembrane helix was shown to be almost perpendicular to the membrane normal. Secondly, the starting positions of the globular domain were selected upon epitope labeling and the globular domain was merged to the transmembrane helix. After that three parallel simulations were produced with united atom force field for total time of 250 ns. Final model was then compared to all known experimental data as shown in the section *Final model cross-validation* in the Results.



### References

- Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.; McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.; Gibson, T. J.; Higgins, D. G. *Bioinformatics*. 2007, 23, 2947-8.
- (2) Waterhouse, A. M.; Procter, J. B.; Martin, D. M. a; Clamp, M.; Barton, G. J. *Bioinformatics*. **2009**, *25*, 1189-91.
- (3) Bridges, A.; Gruenke, L.; Chang, Y. T.; Vakser, I. A.; Loew, G.; Waskell, L. J. Biol. *Chem.* **1998**, *273*, 17036-49.
- (4) Black, S. D.; Martin, S. T.; Smith, C. A. *Biochemistry*. **1994**, *33*, 6945-51.
- (5) Black, S. D. *The FASEB Journal*. **1992**, *6*, 680-685.
- (6) Wachenfeldt, C. von; Johnson, E. F. In *Cytochrome P450: Structure, Mechanism, and Biochemistry*; Plenum Press: New York, 1995; p. 183–244.
- (7) Cosme, J.; Johnson, E. F. J. Biol. Chem. 2000, 275, 2545-2553.
- (8) Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinković, D.; Jhoti, H. *Nature*. **2003**, *424*, 464-8.
- (9) Ramadurai, S.; Holt, A.; Krasnikov, V.; Bogaart, G. van den; Killian, J. A.; Poolman, B. *J. Am. Chem. Soc.* **2009**, *131*, 12650-6.
- (10) Szczesna-Skorupa, E.; Chen, C. D.; Rogers, S.; Kemper, B. *Proc. Natl. Acad. Sci. USA*. **1998**, *95*, 14793-8.
- (11) DeLano, W. L. *The PyMOL Molecular Graphics System*, <u>http://pymol.org</u>, 0.99rc6; DeLano Scientific: Palo Alto, CA, USA, **2002**.